Change and predictive ability of circulating immunoregulatory lymphocytes in long-term outcomes of acute ischemic stroke. Issue 9 (September 2021)

• Record Type: Journal Article
• Authors: Li, Sicheng; Huang, Yichen; Liu, Yang; Rocha, Marcelo; Li, Xiaofan; Wei, Pengju; Misilimu, Dilidaer; Luo, Yunhe; Zhao, Jing; Gao, Yanqin
• Is Part Of: Journal of cerebral blood flow & metabolism. Volume 41:Issue 9(2021)
• Page Start: 2280
• Page End: 2294
• Publication Date: 2021-09
• Subjects: Circulating lymphocytes -- flow cytometry -- ischemic stroke -- regulatory B cells -- regulatory T cells; Cerebral circulation -- Periodicals; Brain -- Metabolism -- Periodicals; Brain -- Blood-vessels -- Periodicals; Cerebrovascular disease -- Periodicals; 612.824
• DOI: 10.1177/0271678X21995694
• Languages: English
• ISSNs: 0271-678X

Abstract

Lymphocytes play an important role in the immune response after stroke. However, our knowledge of the circulating lymphocytes in ischemic stroke is limited. Herein, we collected the blood samples of clinical ischemic stroke patients to detect the change of lymphocytes from admission to 3 months after ischemic stroke by flow cytometry. A total of 87 healthy controls and 210 patients were enrolled, and the percentages of circulating T cells, CD4 + T cells, CD8 + T cells, double negative T cells (DNTs), CD4 + regulatory T cells (Tregs), CD8 + Tregs, B cells and regulatory B cells (Bregs) were measured. Among patients, B cells, Bregs and CD8 + Tregs increased significantly, while CD4 + Tregs dropped and soon reversed after ischemic stroke. CD4 + Tregs, CD8 + Tregs, and DNTs also showed high correlations with the infarct volume and neurological scores of patients. Moreover, these lymphocytes enhanced the predictive ability of long-term prognosis of neurological scores when added to basic clinical information. The percentage of CD4 + Tregs within lymphocytes showed high correlations with both acute and long-term neurological outcomes, which exhibited a great independent predictive ability. These findings suggest that CD4 + Tregs can be a biomarker to predict stroke outcomes and improve existing therapeutic strategies of immunoregulatory lymphocytes.